Role of TP53 Gene in Hematolymphoid Malignancies and Multiple Myeloma

Date & Time: 22nd May, 2020; 4pm – 5pm

Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers, including leukemias, lymphomas and myelomas. Tumor suppressor p53 protein (cellular tumor antigen p53), is “the guardian of the genome,” preserves genome stability under cellular stress, and is involved in various processes of development, differentiation, aging, and disease.

Dysfunction of p53 in human cancers can result from deletion, mutations, and dysregulation of TP53 gene expression and other p53 related activities. These mechanisms provide multiple ways to inactivate the functions of the TP53 pathway. This opens up a wide spectrum of applications of TP53 gene testing for hematolymphoid malignancies as well as Multiple Myeloma.

Next Gen Sequencing for Next Gen Clinician: Difficult Codes Demystified!

Date & Time: 21st May, 3 pm

Next generation sequencing is slowly replacing the traditional technologies for the diagnosis of genetic disorders. Instead of gene-by-gene approach, large sets or panel of genes can now be analysed in a single test. The widespread application of NGS in research has led to its broad acceptance as a diagnostic tool, thereby replacing most of the other molecular diagnostic technologies.


Implementation of NGS technology into routine diagnostics requires strategic choices and specific guidelines and protocols to be followed. Clinical healthcare providers can be confident in explaining the NGS results to the patient when they understand the strengths and weaknesses of the bioinformatic analytics that generated the data for interpretation.

Basics of genetic testing in Myeloproliferative neoplasms and understanding test reports

30 May 2020, Sunday


This video covers basics of genetic testing, clinical applications in Myeloproliferative Neoplasms and understanding test reports

AML Risk Stratification – Understanding Fragment Analysis and NGS panel test results

30 May 2020, Sunday


This video talks about Acute Myeloid Leukemia (AML) risk stratification, FLT3 testing in AML and understanding the test reports.

Inborn Errors of Metabolism

Part 1 – Inborn Errors of Metabolism – What a Clinician needs to know!

  8th May 2020, 4PM

Part 2 – Next Generation Sequencing (NGS) for diagnosis of Inborn Errors of Metabolism


12th May 2020, 4PM